BCRX icon

BioCryst Pharmaceuticals
BCRX

Overview Fund Activity

233 hedge funds and large institutions have $1.24B invested in BioCryst Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 101 increasing their positions, 57 reducing their positions, and 22 closing their positions.

Holders
233
Holders Change
-3
Holders Change %
-1.27%
% of All Funds
3.72%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
21
Increased
101
Reduced
57
Closed
22
Calls
$22.4M
Puts
$5.79M
Net Calls
+$16.6M
Net Calls Change
+$3.11M

Top Buyers

1
B
1
Braidwell
Connecticut
$38M
2
DM
2
Deerfield Management
New York
$23.3M
3
Nuveen Asset Management
3
Nuveen Asset Management
Illinois
$18.2M
4
BlackRock
4
BlackRock
New York
$119M
5
Morgan Stanley
5
Morgan Stanley
New York
$12.9M

Top Sellers

1
Assenagon Asset Management
1
Assenagon Asset Management
Luxembourg
$7.86M
2
State Street
2
State Street
Massachusetts
$74.1M
3
Point72 Asset Management
3
Point72 Asset Management
Connecticut
$19.5M
4
Fisher Asset Management
4
Fisher Asset Management
Washington
$22.6M
5
Jacobs Levy Equity Management
5
Jacobs Levy Equity Management
New Jersey
$3.33M
Name Holding Trade Value Shares
Change 		Shares
Change %
TWC
251
TD Waterhouse Canada
Ontario, Canada
– -$932 -100 Closed
VCM
252
Versant Capital Management
Arizona
– -$415 -59 Closed
DI
253
Disciplined Investments
Oklahoma
– -$127 -18 Closed
7 8 9 10
11